Navigation Links
Reportlinker Adds Global Bipolar Disorder Industry
Date:6/24/2010

NEW YORK, June 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Bipolar Disorder Industry

http://www.reportlinker.com/p0209267/Global-Bipolar-Disorder-Industry.html

This report analyzes the worldwide markets for Bipolar Disorder in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company, Forest Laboratories, Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica, Inc., Parent Company Profile - Johnson and Johnson Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer, Inc., Repligen Corporation, and Validus Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

BIPOLAR DISORDER MCP-6202

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Atypical anti-psychotics I-3

Other Therapeutics I-3

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW II-1

Bipolar Disorder Facts II-1

A Market with Unmet Medical Needs II-1

A Major Burden on Society II-2

Current and Future Analysis II-2

Patent Expiries Depress Market Growth II-3

Patent Expiries of Major Bipolar Disorder Drugs II-3

Loss of Exclusivity to Continue II-3

Poor Pipeline Dims Prospects for Market Growth II-3

A Few Bright Spots II-4

Opportunities and Challenges II-4

The Clinicians' Quest for The Best - Seroquel XR II-5

Children and Teens - The Targets or the Beneficiaries! II-5

Adverse Events - A Major Issue with Antipsychotics II-6

Side Effects Influence Prescription Trends II-6

2. COMPETITIVE LANDSCAPE II-7

A Market Sans Competition II-7

Bipolar Disorder Drugs Market (2009): Five Major Companies

with Marketed Products II-7

Antipsychotics - The Mainstay Therapy II-7

Table 1: Leading Players in Global Antipsychotic Drugs

Market (2008): Annual Sales and Market Share Breakdown for

Eli Lilly, AstraZeneca, Johnson & Johnson, Bristol-Myers

Squibb, GlaxoSmithKline, and Pfizer (includes corresponding

Graph/Chart) II-8

Antidepressants II-8

Table 2: Leading Drugs in the Global Antidepressants Market

(2008): Revenues and Market Share Breakdown for Effexor,

Cymbalta, Lexapro, Paxil/Wellbutrin, Zoloft and Remeron

(includes corresponding Graph/Chart) II-9

Antiepileptics - Prescriptions Continue Despite Warning II-9

Select Antiepileptics with Approved Bipolar Disorder

Indications II-10

Table 3: Leading Players in the Global Antiepileptics Market

(2008): Revenue in US$ Million and Market Share Breakdown

for Pfizer, Johnson & Johnson, UCB Pharma, Abbott,

GlaxoSmithKline and Others (includes corresponding

Graph/Chart) II-10

3. A REVIEW OF SELECT LEADING DRUGS II-11

Abilify (Aripiprazole) II-11

Geodon/Zeldox (Ziprasidone) II-11

Invega (Paliperidone) II-11

Lamictal (Lamotrigine) II-11

Risperdal (Risperidone) II-12

Risperdal® Consta® (Risperidone) II-12

Saphris (Asenapine) II-13

Seroquel (Quetiapine) II-13

Seroquel XR II-13

Zyprexa (Olanzapine) II-14

Other Drugs II-14

Depakine (Sodium Valproate) II-14

Depakote/ Depakote ER (Divalproex Sodium) II-15

Tegretol (Carbamazepine) II-15

4. PIPELINE ANALYSIS II-16

A Few Battle Big Challenges II-16

Drug Development Pipeline for Select Bipolar Disorder Candidates II-16

Bipolar Disorder Drugs (2009) -Select Companies with Products

in Late Stage Clinical Development (Phase II, III, Pending

Approvals) II-17

A Review of Select Leading Pipeline Candidates II-17

Lurasidone (SM-13,496) II-17

Zomaril II-17

Nuvigil (armodafinil) II-17

RG2417 (Uridine) II-17

RGH-188 (Cariprazine) II-18

AZ - 004 (Staccato Loxapine) II-18

Lu AA39959 II-18

Lu AA34893 II-18

5. DISEASE OVERVIEW II-19

Introduction II-19

History II-19

Causes of Bipolar Disorder II-20

Triggers II-20

Episodes in a Bipolar Disorder II-21

Classification of Bipolar Disorder II-21

Bipolar Disorder Classification II-21

Symptoms of Various Types of Bipolar Disorder II-21

Mania II-21

Hypomania II-22

Mixed State II-22

Depression II-22

Additional Symptoms of Bipolar Episode II-23

Treatment of Bipolar Disorder II-23

Psychosocial Treatments II-24

Hospitalization for Extreme Cases II-24

6. CLINICAL TRIALS II-25

Cephalon Announces Promising Phase II Clinical Results of NUVIGIL II-25

Repligen Commences Phase IIB Trial of RG2417 II-25

Forest and Gedeon Richter Announce Favorable Phase II Results

for Cariprazine II-25

Alexza Commences Preliminary Phase 3 Trail with Staccato®

Loxapine II-26

Dainippon Sumitomo to Conduct Clinical Study for Lurasidone II-26

7. PRODUCT APPROVALS AND LAUNCHES II-27

AstraZeneca Introduces Seroquel XR® in North America II-27

AstraZeneca Introduces Seroquel XR in Europe II-27

Wockhardt to Roll Out Divalproex ER Tablets II-27

FDA Approves SEROQUEL for Paediatric Treatment of

Schizophrenia and Bipolar Disorder II-27

FDA Approves Eli Lilly's Zyprexa for Schizophrenia and Bipolar

Indications II-28

Pfizer Canada Receives Approval from Health Canada for ZELDOX II-28

Ortho-McNeil-Janssen Receives FDA Approval for RISPERDAL® CONSTA® II-28

FDA Grants Approval to Eurand for EUR-1048 II-28

Merck/Schering-Plough Receives EMEA Approval for SYCREST® II-29

FDA Approves SAPHRIS(R) for Treatment of Mixed/Manic Episodes

of Bipolar Disorder and for Acute Treatment of Schizophrenia

in Adults II-29

FDA Grants Marketing Approval to Glenmark for Lithium

Carbonate Capsules II-29

Ranbaxy Australia Receives Approval from Therapeutic Goods

Administration II-29

Servier Obtains Approval for Valdoxan®/Thymanax® II-29

Pfizer Canada Receives Approval from Health Canada for ZELDOX

Drug II-30

Pfizer Obtains Extended Approval for Geodon II-30

FDA Considers Approval of Psychiatric Medications for Children II-30

FDA Weighs Zyprexa for Two Juvenile Indications II-30

Caraco Pharmaceutical Introduces Divalproex Sodium Delayed

Release Tablets II-31

BMS and Otsuka Obtain European Marketing Approval for ABILIFY®

for Manic Episodes II-31

ABILIFY® Obtains Extended Indications in Schizophrenia and

Bipolar I Disorder II-31

AstraZeneca Receives European MRP Approval for SEROQUEL and

SEROQUEL XR II-32

FDA Approves Seroquel XR® Extended Release Tablets II-32

Mylan Pharmaceuticals Receives FDA Approval for Risperidone

Tablets USP II-32

Depakote Generic Drug Receives FDA Approval II-32

Noven Pharmaceuticals Receives FDA Approval for Stavzor™ II-33

BMS and Otsuka Receive FDA Approval for ABILIFY® II-33

Lupin Obtains FDA Approval for Divalproex Sodium Delayed-

Release Tablets II-33

Orchid Chemicals Obtains FDA Approval for Divalproex Sodium

Delayed II-33

Noven Pharmaceuticals Receives FDA Approval for Stavzor Capsules II-33

Sun Pharmaceutical Industries Receives USFDA Approval for

Depakote Divalproex Sodium Tablets II-34

8. RECENT INDUSTRY ACTIVITY II-35

Abbott Takes Over Solvay Pharmaceuticals II-35

Merck & Co. Merges with Schering-Plough II-35

Pfizer Acquires Wyeth II-35

Hisamitsu Pharmaceutical and Hisamitsu U.S. Take Over Noven

Pharmaceuticals II-35

Avacta Group Acquires TheraGenetics II-36

BMS and Otsuka Extend their Agreement on Ability II-36

ADA Technologies to Develop Home Lithium-Monitor for Bipolar

Disorder II-36

Repligen Licenses Global Rights for Bipolar Disorder Treatment II-36

SUN Pharmaceutical Industries to Divest Assets and Rights of

Generic Drugs II-37

AstraZeneca Signs Agreement with Abraxis BioScience II-37

Roche Holding to Acquire Memory Pharmaceuticals II-37

Scientists Find Common Genetic Profile between BPD and

Schizophrenia II-37

Wyeth Terminates Bifeprunox Accord with Solvay II-37

Noven Pharmaceuticals Takes Over JDS Pharmaceuticals II-38

9. FOCUS ON SELECT GLOBAL PLAYERS II-39

Abbott Laboratories, Inc. (US) II-39

AstraZeneca PLC (UK) II-39

Bristol-Myers Squibb Company (US) II-39

Cephalon, Inc. (USA) II-40

Dainippon Sumitomo Pharma Co. Ltd. (Japan) II-40

Eli Lilly and Company (US) II-41

Table 4: Eli Lilly's Leading Products (2009): Global Revenues

in US$ Billion by Product - Zyprexa, Cymbalta, Humalog,

Alimta, Cialis, Gemzar, Evista and Humulin (includes

corresponding Graph/Chart) II-42

Forest Laboratories, Inc. (US) II-42

Gedeon Richter PLC (Hungary) II-42

GlaxoSmithKline PLC (UK) II-43

H. Lundbeck A/S (Denmark) II-43

Janssen Pharmaceutica, Inc. (US) II-43

Parent Company Profile - Johnson and Johnson Company (US) II-44

Merck & Co., Inc. (US) II-44

Otsuka America Pharmaceutical Inc. (US) II-45

Pfizer, Inc. (US) II-45

Repligen Corporation (US) II-45

Validus Pharmaceuticals, Inc. (US) II-46

10. GLOBAL MARKET PERSPECTIVE II-47

Table 5: World Recent Past, Current & Future Analysis for

Bipolar Disorder Drugs by Geographic Region - US, Europe,

Asia-Pacific and Rest of World Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2006

through 2015 (includes corresponding Graph/Chart) II-47

Table 6: World 10-Year Perspective for Bipolar Disorder Drugs

by Geographic Region - Percentage Breakdown of Dollar Sales

for US, Europe, Asia-Pacific, and Rest of World Markets for

Years 2006, 2009, and 2015 (includes corresponding

Graph/Chart) II-48

Table 7: World Recent Past, Current & Future Analysis for

Bipolar Disorder Drugs by Therapeutic Class - Atypical

Anti-Psychotics, and Other Therapeutics Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2006

through 2015 (includes corresponding Graph/Chart) II-49

Table 8: World 10-Year Perspective for Bipolar Disorder Drugs

by Therapeutic Class - Percentage Breakdown of Dollar Sales

for Atypical Anti-Psychotics, and Other Therapeutics for Years

2006, 2009, and 2015 II-49

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current and Future Analysis III-1

Bipolar Disorder Facts III-1

Major Trends III-1

Mental Healthcare Expenditure Rising in the US III-1

Antidepressants Grow as First-line Therapy for New Patients III-2

Treatment for Bipolar Disorder Differs Based on Physician

Specialty III-2

American Children Prescribed More Psychotropic Drugs than

European Children III-3

Product Launches III-3

Drug Approvals III-4

Strategic Corporate Developments III-9

Key Players III-12

Abbott Laboratories, Inc. III-12

Bristol-Myers Squibb Company III-12

Eli Lilly and Company III-13

Table 9: Eli Lilly's Leading Products (2009): Breakup of

Global Revenues in US$ Billion by Product - Zyprexa,

Cymbalta, Humalog, Alimta, Cialis, Gemzar, Evista and

Humulin (includes corresponding Graph/Chart) III-14

Forest Laboratories, Inc. III-14

Janssen Pharmaceutica, Inc. III-14

Merck & Co., Inc. III-15

Otsuka America Pharmaceutical, Inc. III-15

Pfizer, Inc. III-16

Repligen Corp. III-16

Validus Pharmaceuticals, Inc. III-16

B.Market Analytics III-17

Table 10: US Recent Past, Current & Future Analysis for

Bipolar Disorder Drugs - Annual Sales Figures in US$ Million

for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-17

2. EUROPE III-18

A.Market Analysis III-18

Current and Future Analysis III-18

Product Launch III-18

Drug Approvals III-18

B.Market Analytics III-20

Table 11: European Recent Past, Current & Future Analysis

for Bipolar Disorder Drugs by Geographic Region - France,

Germany, Italy, the UK, Spain, and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-20

Table 12: European 10-Year Perspective for Bipolar Disorder

Drugs by Geographic Region - Percentage Breakdown of Dollar

Sales for France, Germany, Italy, the UK, Spain, and Rest of

Europe Markets for Years 2006, 2009, and 2015 (includes

corresponding Graph/Chart) III-21

2A. FRANCE III-22

A.Market Analysis III-22

Current and Future Analysis III-22

B.Market Analytics III-22

Table 13: French Recent Past, Current & Future Analysis for

Bipolar Disorder Drugs - Annual Sales Figures in US$ Million

for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-22

2B. GERMANY III-23

A.Market Analysis III-23

Current and Future Analysis III-23

B.Market Analytics III-23

Table 14: German Recent Past, Current & Future Analysis for

Bipolar Disorder Drugs - Annual Sales Figures in US$ Million

for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-23

2C. ITALY III-24

A.Market Analysis III-24

Current and Future Analysis III-24

B.Market Analytics III-24

Table 15: Italian Recent Past, Current & Future Analysis for

Bipolar Disorder Drugs - Annual Sales Figures in US$ Million

for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-24

2D. THE UNITED KINGDOM III-25

A.Market Analysis III-25

Current and Future Analysis III-25

Treatment Overview III-25

List of Licensed Drugs for Bipolar Disorder Treatment III-25

Lithium and Valproate Semisodium - Prescription Trends III-26

Strategic Corporate Development III-26

Key Players III-26

AstraZeneca PLC III-26

GlaxoSmithKline PLC III-27

B.Market Analytics III-27

Table 16: The UK Recent Past, Current & Future Analysis for

Bipolar Disorder Drugs - Annual Sales Figures in US$ Million

for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-27

2E. SPAIN III-28

A.Market Analysis III-28

Current and Future Analysis III-28

B.Market Analytics III-28

Table 17: Spanish Recent Past, Current & Future Analysis for

Bipolar Disorder Drugs - Annual Sales Figures in US$ Million

for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-28

2F. REST OF EUROPE III-29

A.Market Analysis III-29

Current and Future Analysis III-29

Key Players III-29

Gedeon Richter PLC (Hungary) III-29

H. Lundbeck A/S (Denmark) III-29

B.Market Analytics III-30

Table 18: Rest of Europe Recent Past, Current & Future

Analysis for Bipolar Disorder Drugs - Annual Sales Figures

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-30

3. ASIA-PACIFIC III-31

A.Market Analysis III-31

Current and Future Analysis III-31

Australia III-31

Bipolar Disorder Facts III-31

Product Approval III-32

B.Market Analytics III-32

Table 19: Asia-Pacific Recent Past, Current & Future

Analysis for Bipolar Disorder Drugs - Annual Sales Figures

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-32

4. REST OF WORLD III-33

A.Market Analysis III-33

Current and Future Analysis III-33

Product Approval III-33

Key Player III-33

Dainippon Sumitomo Pharma Co. Ltd. (Japan) III-33

B.Market Analytics III-34

Table 20: Rest of World Recent Past, Current & Future

Analysis for Bipolar Disorder Drugs - Annual Sales Figures

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-34

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 64)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 35

Canada 2

Japan 4

Europe 16

France 3

Germany 1

The United Kingdom 4

Rest of Europe 8

Asia-Pacific (Excluding Japan) 5

Middle East 2

------------------------------------------

To order this report:

Pathology Industry: Global Bipolar Disorder Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Cystic Fibrosis Industry
2. Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
3. Reportlinker Adds China Patient Monitoring Market Outlook to 2016
4. Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
5. Reportlinker Adds China Cardiovascular Devices Market Outlook to 2016
6. Reportlinker Adds Medical Device Distributors - Europe
7. Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
8. Reportlinker Adds Global Pulmonary Drug Delivery Technologies industry
9. Reportlinker Adds Global HIV Drugs industry
10. Reportlinker Adds Ophthalmic Therapeutic Drugs: Technologies and Global Markets
11. Reportlinker Adds Antifungal Drugs: Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions and ... M&A achieved through NPS and Dyax acquisitions and the announced ... achieved through NPS and Dyax acquisitions and the announced combination ... most robust pipeline in Shire , s history ... robust pipeline in Shire , s history   ...
(Date:2/11/2016)... --> --> ... report, titled "Sports Medicine Devices Market - Global Industry Analysis, ... to the report, the global sports medicine devices market is ... 2019, growing from a value of US$6.1 bn in 2012 ... --> The global sports medicine devices market is ...
(Date:2/11/2016)... , February 11, 2016 F ast ... answers at the ... world-leading provider of scientific, technical and medical information products and services, has ... evidence-based, peer reviewed clinical information via a mobile device. Elsevier designed the ... for Nursing. The new app is available in Android and ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 2016 , ... The annual list showcases the 20 Most Promising SharePoint Solution ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members of ... to recognize and promote technology entrepreneurship. , The survey was made at the ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed ... CA, on February 6th & 7th, 2016 according to kicking coach Michael Husted. , ... invited to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third ...
(Date:2/10/2016)... ... February 10, 2016 , ... President Obama’s ... Advantage organizations to deliver medical services via telehealth, estimated to generate more than ... for such language for many years. Although there is more to be ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... full-service health care communications company offering education, research and medical media, has ... and specialists working in infectious diseases. , As the all-inclusive resource for ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Academy of Emergency Medicine , an emergency medicine professional association, to support the ... . , The American Academy of Emergency Medicine, or AAEM, seeks to empower ...
Breaking Medicine News(10 mins):